NCT05692492View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

June 3, 2023

Primary Completion Date

June 16, 2026

Study Completion Date

December 16, 2026

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG

ZSP1601

50mg BID

DRUG

ZSP1601

100mg BID

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

NanFang Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY